Jupiter Topco LLC Takes $883,000 Position in Omnicell, Inc. $OMCL

Jupiter Topco LLC acquired a new stake in Omnicell, Inc. (NASDAQ:OMCL) in the 2nd quarter, Holdings Channel.com reports. The institutional investor acquired 21,267 shares of the company’s stock, valued at approximately $883,000.

Several other hedge funds and other institutional investors also recently added to or reduced their stakes in the business. Hsbc Holdings PLC purchased a new position in Omnicell during the 2nd quarter valued at about $381,000. Canada Pension Plan Investment Board bought a new position in shares of Omnicell during the second quarter valued at approximately $673,000. Legal & General Group Plc bought a new position in shares of Omnicell during the second quarter valued at approximately $7,194,000. The Manufacturers Life Insurance Company purchased a new position in Omnicell during the second quarter valued at approximately $928,000. Finally, Algert Global LLC raised its stake in Omnicell by 147.9% in the second quarter. Algert Global LLC now owns 25,392 shares of the company’s stock worth $1,054,000 after buying an additional 15,150 shares in the last quarter. 97.70% of the stock is currently owned by institutional investors.

Analyst Upgrades and Downgrades

Several brokerages have issued reports on OMCL. Zacks Research cut Omnicell from a “hold” rating to a “strong sell” rating in a research report on Friday, August 7th. Wall Street Zen upgraded Omnicell from a “buy” rating to a “strong-buy” rating in a research note on Sunday, May 10th. Piper Sandler reaffirmed an “overweight” rating and set a $45.00 price objective (down from $55.00) on shares of Omnicell in a research report on Monday, August 3rd. Wells Fargo & Company cut their target price on Omnicell from $55.00 to $50.00 and set an “overweight” rating on the stock in a research note on Friday, July 31st. Finally, Weiss Ratings upgraded shares of Omnicell from a “hold (c-)” rating to a “hold (c)” rating in a report on Tuesday, August 18th. Seven equities research analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has issued a Sell rating to the company. According to data from MarketBeat.com, Omnicell presently has a consensus rating of “Moderate Buy” and an average target price of $57.86.

Omnicell Price Performance

NASDAQ OMCL opened at $34.37 on Friday. The firm’s fifty day simple moving average is $39.34 and its two-hundred day simple moving average is $39.24. The firm has a market capitalization of $1.56 billion, a P/E ratio of 40.92, a P/E/G ratio of 0.86 and a beta of 0.97. The company has a current ratio of 1.64, a quick ratio of 1.43 and a debt-to-equity ratio of 0.13. Omnicell, Inc. has a 12-month low of $29.06 and a 12-month high of $55.00.

Omnicell (NASDAQ:OMCL) last posted its quarterly earnings data on Thursday, July 30th. The company reported $0.94 earnings per share for the quarter, topping analysts’ consensus estimates of $0.47 by $0.47. Omnicell had a return on equity of 5.66% and a net margin of 3.13%.The firm had revenue of $312.21 million during the quarter, compared to analysts’ expectations of $310.21 million. During the same quarter last year, the firm earned $0.45 EPS. The business’s quarterly revenue was up 7.4% on a year-over-year basis. Omnicell has set its Q3 2026 guidance at 0.350-0.430 EPS and its FY 2026 guidance at 2.150-2.300 EPS. Analysts forecast that Omnicell, Inc. will post 1.41 EPS for the current fiscal year.

Omnicell Profile

Omnicell, Inc is a healthcare technology company that specializes in medication management solutions for hospitals, clinics and pharmacies. The company’s offerings encompass automated dispensing cabinets, pharmacy automation systems, IV compounding devices, and software platforms designed to optimize medication usage, streamline workflow and improve patient safety. Omnicell’s analytics and inventory management tools provide real-time visibility into medication utilization, helping healthcare providers reduce waste, manage controlled substances and ensure regulatory compliance.

Founded in Mountain View, California in 1992, Omnicell has grown through both internal innovation and strategic acquisitions to broaden its portfolio across the medication management continuum.